C
Caris Life Sciences
A profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics
About Caris Life Sciences
Caris Life Sciences is a pioneering company that operates at the intersection of molecular science and artificial intelligence, with a primary focus on revolutionizing cancer care. The company provides comprehensive molecular information to cancer patients and oncologists, aiding in the development of personalized treatment plans. This is achieved by understanding the molecular features of a cancer when the diagnosis is made, which can provide insights into how the cancer may behave and what treatments may be most effective.
Read full description
Caris Life Sciences' business model is centered on providing high-quality, reliable molecular information to help improve the lives of as many people as possible. The company's clients are primarily oncologists and cancer patients, but also include researchers and payors in the healthcare sector. The company generates revenue by offering its transformative technologies and services to these clients, thereby helping them navigate, advance, and reinvent cancer care.
The company is committed to quality and innovation, and this is reflected in its hiring practices. Caris Life Sciences seeks to employ the brightest minds in scientific, medical, and professional fields to help fulfill the promise of personalized medicine. The company's dedication to its mission is evident in the opportunities it provides to its employees, as well as in the positive experiences shared by team members.
In summary, Caris Life Sciences is a leading innovator in molecular science, using artificial intelligence to revolutionize cancer care by providing comprehensive molecular information to patients, oncologists, researchers, and payors.
At a glance
- Founded
- 1996
- Headquarters
- Irving, United States
- Listing
- IPO 2025
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Caris Life Sciences.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later23 investors entered at this stage
Sixth Street Growth
Coatue Management
Neuberger Berman
Millennium Management- FMFirst Light Asset Management
OrbiMed
Highland Capital Management
ClearBridge Investments
T. Rowe Price
Silver Lake Partners
Fidelity Investments- PIPura Vida Investments
CPP Investments- CIColumbia Threadneedle Investments
Tudor Group
Rock Springs Capital
Eaton Vance Management
Braidwell
Woodline Partners
Perceptive Advisors- GPGhisallo Partners
Blackstone
Blue Owl Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
23 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Caris Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Caris Life Sciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.